Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

The new Joe Biden White House agenda “rests on a foundation provided by the nation’s nearly 600,000 miners — miners and a mining industry ready to do their parts to help drive America’s post-pandemic recovery,” according to recent NWITimes article (https://ibn.fm/cSMsr). That agenda is welcomed by U.S. mining companies, including Energy Fuels (NYSE American: UUUU) (TSX: EFR), the country’s largest producer of uranium, who also expects to become a producer of an intermediate rare earth element (“REE”) product in early 2021. Also today, the company was featured in a publication from MiningNewsWire, examining how, during his state of the state address, Nevada Governor Steve Sisolak included a section that addressed the new energy economy. He pledged to work on energy laws, explaining that the state had the opportunity to grow. Additionally, the company was featured in a MiningNewsBreaks from MiningNewsWire, examining how UUUU recently finalized a three-year agreement with the Chemours Company (NYSE: CC) to obtain natural monazite ore, one of the world’s highest-grade rare earth element (“REE”) minerals. Under the agreement, Energy Fuels will receive a minimum of 2,500 tons per year of the mineral, which represents a significant step in UUUU’s commitment to be a leader in re-establishing a fully integrated U.S. REE supply chain. 

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

• White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
• Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
• Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

• Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
• Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
• Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

• La Sal Complex (Utah)
• Whirlwind Mine (Colorado/Utah)
• Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Friday’s trading session at $4.87, up 16.2291%, on 10,062,350 volume with 29,140 trades. The average volume for the last 3 months is 4,016,719 and the stock's 52-week low/high is $0.779999971/$4.9499998.

Recent News

• Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Eager to Be Part of Biden's Plan of 'Bringing Home Critical Supply Chains'
• Nevada Plans to Mine More Lithium as EV Sector Increases Demand
• MiningNewsBreaks - Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Makes Significant Step in Commitment to Reestablish US REE Supply Chain

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF)

The QualityStocks Daily Newsletter would like to spotlight TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF).

TAAT Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF)  was featured today in a publication detailing various investment considerations and how the company is “One to Watch.”

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) is a life sciences company dedicated to giving legal-aged smokers the choice to keep the smoking experience that they enjoy with no nicotine and no tobacco.

The key players of TAAT Lifestyle & Wellness are from leading tobacco brands. They are guiding the mission with the company’s proprietary product, TAAT(TM), which uses the company’s proprietary Beyond Tobacco(TM) base material. The base material undergoes a 14-step process to taste and smell just like tobacco and uses a patent-pending refinement technique.

This provides the company with unique opportunities on the global tobacco market, which was estimated at $849 billion in 2019, with approximately 1.3 billion people using tobacco in some form worldwide (https://nnw.fm/bvKFL).

TAAT Lifestyle & Wellness was founded in 2006 and is headquartered in Vancouver, Canada, with operations in Las Vegas, Nevada.

TAAT(TM)

TAAT is a smokable alternative to tobacco cigarettes using the Beyond Tobacco base material, which contains zero tobacco and zero nicotine. The current TAAT offering comes in three varieties: Original, Smooth and Menthol, which were launched during Q4 2020 in Ohio. The company’s Ohio tobacco wholesaler also distributes for major tobacco industry names such as Altria, RJ Reynolds (a subsidiary of British American Tobacco) and ITG.

The TAAT Beyond Tobacco experience was created to replicate the sensory elements of smoking a tobacco cigarette. Market testing in California and Nevada reached a consensus that TAAT products offered no significant differences in experience when compared to tobacco cigarettes, in terms of the following aspects:

• Visual – the nearly identical product packaging and enhanced smoke volume
• Auditory – the “crackling” sound of the base material when it is ignited
• Smell – when burning, TAAT emits a tobacco-like scent
• Taste – the patent-pending Beyond Tobacco base material undergoes a refinement process that creates a tobacco-like taste
• Touch – TAAT satisfies the “hand-to-mouth” fixation and motor habits, such as flicking ashes

TAAT Beyond Tobacco Targeting Current Smokers

TAAT Lifestyle & Wellness is currently targeting the market of legal-aged smokers with its proprietary product. The company aims “not to create a new problem, but to solve an existing one.” TAAT Lifestyle & Wellness offers a non-addictive alternative to tobacco, with several competitive advantages making it a promising option on the United States market, such as:

• Price – TAAT can be offered at a lower price than competing products in the tobacco category, which adds to the propositioned value for current legal-aged smokers.
• Experience – TAAT appeals to current smokers who wish to give up the tobacco and nicotine but keep the smoking experience they enjoy.
• Branding/Packaging – TAAT is American-grown and American-made, with its Beyond Tobacco base material serving as a legacy to the combustible tobacco products.

The current alternatives to cigarette smoking do not offer a comparable experience. Previously marketed products, like vaping, proved difficult for some legal-aged smokers to adopt, as the experience was too different from traditional cigarettes.

Market Outlook

In 2016, the United States tobacco market was valued at over $100 billion, a number that’s expected to grow over the next decade (https://nnw.fm/yd8oP). In terms of volume, over 215 billion cigarettes were sold to roughly 34 million adults in the United States in 2018. These numbers represent almost 14% of the adult population. Of those, almost two-thirds smoked more than 15 cigarettes in one day. A standard pack is comprised of 20 cigarettes.

The company’s Beyond Tobacco, as a non-tobacco product, has a price-driven consumer advantage in many states. While state taxes on traditional cigarettes vary, most tend to average around $1.82 per pack. Washington D.C. is on the higher end of the tax spectrum at $4.50 per pack, whereas Missouri is only $0.17 per pack (https://nnw.fm/D3WnT).

TAAT Lifestyle & Wellness estimates that, if one pack of TAAT Beyond Tobacco was sold at 20% of all United States tobacco points of sale, the product would capture 0.25% of the market, the equivalent of approximately 2.7 million cartons of cigarettes per year.

Management Team

Setti Coscarella is the Chief Executive Officer of TAAT Lifestyle & Wellness Ltd. He is experienced in investment banking, private equity and entrepreneurship. In 2017, Mr. Coscarella was the lead strategist for Reduced-Risk Products at Philip Morris International. While there, he worked with thousands of smokers to better understand how to position smoking alternatives, developing programs that could help smokers convert to reduced-risk products. Mr. Coscarella holds an MBA from the Schulich School of Business, specializing in finance, marketing and corporate strategy. He also has a Bachelor of Science in mathematics and physics from the University of Toronto.

Tim Corkum is the company’s Chief Revenue Officer. He has a lengthy history in the tobacco industry, having served 21 years at Philip Morris International. Mr. Corkum has experience leading the international commercialization of combustible cigarettes and working on reduced-risk product offerings. During his 21-year tenure, he held senior positions in business development, sales strategy, key account management and corporate affairs. He holds a BA from Carleton University with a concentration in law.

Joe Deighan is Founder of TAAT Lifestyle & Wellness and oversees research and development. He is the founder of vape liquid ‘JJuice’, created in 2012. JJuice was distributed across all of the United States and in 26 other countries, alongside the private label production that was done for other brands. Mr. Deighan sold JJuice in a cash deal that was valued at over $800,000 in 2017. He currently handles all R&D and production for Beyond Tobacco, knowing the product better than anyone else in the company.

TAAT Lifestyle & Wellness Ltd. (TOBAF), closed Friday’s trading session at $2.99, up 9.5238%, on 302,725 volume with 616 trades. The average volume for the last 3 months is 178,020 and the stock's 52-week low/high is $0.100000001/$3.31999993.

Recent News

• TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) Is 'One to Watch'
• InvestorNewsBreaks - TAAT(TM) Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) Featured in Forbes Article
• InvestorNewsBreaks - TAAT(TM) Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) Announces Agreement with CROSSMARK, Could Include 100,000+ Points of Sale

AzurRx BioPharma Inc. (NASDAQ: AZRX)

The QualityStocks Daily Newsletter would like to spotlight AzurRx BioPharma Inc. (NASDAQ: AZRX).

AzurRx BioPharma Inc. (NASDAQ: AZRX) was featured today in a publication from BioMedWire, examining how a team of researchers from Michigan Medicine-University of Michigan conducted a study on post-op pain management that involved 620 patients who had undergone operations in various hospitals across the state. For the study, patients had their use of painkillers tracked and then participated in surveys in the months following their surgeries.

AzurRx BioPharma Inc. (AZRX) is a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins.

The company’s lead drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients suffering from cystic fibrosis and chronic pancreatitis.

AzurRx has already completed two Phase 2 clinical trials for MS1819 and is currently pursuing approval through parallel monotherapy and combination therapy pathways.

The company was founded in 2014 and is headquartered in New York City, with scientific operations in Langlade, France, and clinical operations in Hayward, California.

MS1819 Clinical Trials

The two current ongoing clinical trials for MS1819 in cystic fibrosis (CF) are the Phase 2b Option 2 monotherapy trial and the Phase 2 combination therapy trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (PERT), the current standard of care. Pending the Phase 2b trial outcome, the company intends to initiate a Phase 3 trial in cystic fibrosis.

• Phase 2b CF Option 2 Trial – The study was initiated in Q3 2020, using MS1819 doses in enteric capsule form (2240mg and 4480mg). Topline data for the trial is anticipated in Q1 2021.
• Phase 2 CF Combination Trial – The study was initiated in Q4 2019, using daily dose levels of PERT in combination with MS1819 dosages (700mg, 1120mg and 2240mg). Topline data is anticipated in Q2 2021.

These trials are currently addressing the treatment of EPI in patients with cystic fibrosis and chronic pancreatitis – an established global market with an estimated value in excess of $2 billion that has been growing at a CAGR greater than 20% over the past five years.

Results from AzurRx’s Phase 2b Option 2 trial of MS1819 in cystic fibrosis patients demonstrate that the non-porcine MS1819 lipase is well-tolerated by patients, with no significant safety signals observed at the 2240mg daily dose level.

“[W]e have evaluated four different enteric capsules and identified the best suitable formulation for MS1819 that provides gastroprotection of enzyme content and delayed release into the duodenum,” James Sapirstein, President & CEO of AzurRx, stated in a September 2020 news release (https://ibn.fm/27t4W). “Our clinical program continues to advance, and we are determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy, significantly reducing the pill burden of cystic fibrosis patients.”

Financial Highlights

As of July 2020, AzurRx had raised gross cash capital of $22.1 million, including $15.2 million from Series B convertible preferred stock and warrants in July 2020 and $6.9 million from convertible promissory notes and warrants in December 2019 and January 2020. Notably, AzurRx solidified its financial position and created an effectively debt-free balance sheet by exchanging substantially all of its outstanding convertible notes into the Series B convertible preferred stock financing.

The company secured an additional $2.5 million in French Research Tax Credits, received in 2020, for the years 2017-2019 (https://ibn.fm/Qxk7O).

In a letter to shareholder, Sapirstein noted that ensuring the company maintains sufficient capital to support its business operations has been a key focus. He further stated that the company is in “a financially secure position” to complete its two Phase 2 MS1819 clinical trial programs and to begin preparations in 2021 for a pivotal Phase 3 study.

The company has no current plans to access additional financing, as it believes it has enough cash to fund existing operational and clinical objectives through Q3 2021.

Management Team

James Sapirstein is the President and CEO of AzurRx BioPharma. He was previously the CEO and a board member for ContraVir Pharmaceuticals Inc., which is now known as Hepion Pharmaceuticals Inc. (NASDAQ: HEPA). Mr. Sapirstein has almost 36 years of experience in the pharmaceutical industry, with expertise in drug development and commercialization. He currently serves on the Emerging Companies and Health Section boards of the BIO (Biotechnology Innovation Organization) and is Chairman Emeritus of BioNJ. He earned his Bachelor’s degree in Pharmacy from Rutgers University and has an MBA in management from Fairleigh Dickinson University.

Daniel Schneiderman is the Chief Financial Officer of AzurRx. He previously served as the CFO of Biophytis SA and its U.S. subsidiary, Biophytis, Inc., clinical-stage biotechnology companies focused on the development of pharmaceutical candidates for age-related diseases. He was appointed to the AzurRx position in January 2020, bringing to the team over 18 years of experience in capital markets and finance operations. Mr. Schneiderman holds a degree in economics from Tulane University.

James Pennington, M.D., is the Chief Medical Officer of AzurRx. Before joining the team, he was the Chief Medical Officer and Senior Clinical Fellow for 11 years at Anthera Pharmaceuticals. Before becoming a part of the biotech industry, Dr. Pennington was on the Medical Faculty of Harvard Medical School for 10 years. He received his medical degree from Oregon Health & Science University.

Martin Krusin is the Senior Vice President for Corporate Development at AzurRx. He has 20 years of experience in business development, strategic marketing, financing and operations in the health care, financial services and consulting sectors. Before joining AzurRx, he was the VP for Business Development at FluoroPharma Medical Inc. Mr. Krusin received his MBA from Columbia Business School in finance and marketing, an MPhil. in political economy from Oxford University and a BA in international relations from Swarthmore College.

Dinesh Srinivasan, Ph.D., is the Vice President for Translational Research at AzurRx. He has over 15 years of experience leading drug discovery and development in the pharmaceutical industry. He began his career as a post-doctorate fellow at Roche Palo Alto. Dr. Srinivasan received his MSc in Biotechnology from the University of Mumbai, India, and a Ph.D. in Pharmacology and Toxicology from the University of Arizona – Tucson.

Ted Stover is the Product Development Director at AzurRx. He joined the company in 2020 to oversee CMC and Project Management. Before joining AzurRx, he spent 20 years focused on manufacturing operations and analytical method development for all stages of pharmaceutical drug development. Mr. Stover earned his MBA from the University of Florida.

AzurRx BioPharma Inc. (AZRX), closed Friday’s trading session at $1.54, up 0.653595%, on 2,787,995 volume with 6,012 trades. The average volume for the last 3 months is 6,925,233 and the stock's 52-week low/high is $0.370867997/$2.63000011.

Recent News

• Study Finds Post-Op Pain-Management Medication Doesn't Have to Include Opioids
• BioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in First Cohort of MS1819 Study
• Study Reveals Connection Between Mental Health Issues and Obesity in Adolescents

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT)

The QualityStocks Daily Newsletter would like to spotlight Blue Hat Interactive Entertainment Technology (BHAT).

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) was featured today in a publication from PennyStocks.com, examining how, one of the topics of discussion recently has been on international relations & some penny stocks may have show pent-up momentum in a few names. The previous administration set out to change U.S.-China trade deals. Tensions rose, and the rest is history. Now, with a new administration, the current dealings in place are under review. While there was a risk of many Chinese companies being delisted from U.S. exchanges, that fear seems to have subsided.

Blue Hat Interactive Entertainment Technology (BHAT) is a cutting-edge creator, developer and operator of popular augmented reality (“AR”) interactive smart toys and educational games in China. Blue Hat’s mobile-connected entertainment platform connects physical items to mobile devices through wireless technologies, creating a unique interactive user experience in various mobile games, interactive educational materials and toys with mobile game features.

Blue Hat designs original toys and games that utilize augmented reality technology, motion capture technology, image recognition technology, voice control, light sense technology, infrared, levitation induction, and other trending scientific technologies to transverse the virtual with reality. Blue Hat creates a rich visual and interactive environment for users through the integration of real objects and virtual scenery. This combination provides users with a more natural form of human computer interaction, enhances a user’s perception of reality, and delivers a more immersive entertainment experience.

Proprietary Technology

Founded in 2010, Blue Hat’s proprietary technology, product research and development, marketing channels and brand operation are the cornerstones of the business. Blue Hat focuses on the combination of “online” and “offline” activity and the interaction between “entertainment” and “product” to create a high-tech entertainment platform combining mobile games and AR. With the help of computer graphics, motion capture technology, image recognition technology and visualization technologies, Blue Hat accurately “places” virtual objects into the physical world, creating a new and stimulating visual environment for users.

Blue Hat recently displayed a variety of its sci-tech products at the Guangzhou International Toy Exhibition in China including AR Racer, Elastic Bubbles, AR Space Track, AR Alloy Toy Car, AR Need a Spanking, 5D Animated Magic Aquarium, Bug Travelers, AR Picture Book and other interactive games and smart toys.

The company has multiple products in development including new generations of four primary product lines and two new product lines.

Patents and Copyrights

Blue Hat’s advanced AR technology in interactive entertainment is protected by 178 authorized patents with 44 patents in various stages of the application process.

Another 14 applications for Patent Cooperation Treaty, or PCT, have been filed for international patents. As of March 31, 2019, the company owns 645 copyrights for artwork, 71 registered trademarks and 27 software copyrights.

Sales and Marketing

There has been rapid growth in the toys and games industry in China over the last several years. Total retail sales of toys and games in China soared from RMB 111.8 billion in 2012 to RMB 276.5 billion in 2017 with an average annual growth rate of 19.9% in 2017. Blue Hat believes the company is well positioned with little competition as the toy industry rapidly shifts toward intelligent and interactive toys and games. Retail sales of electronic toys grew at 24% annually in 2017 while that of traditional toys grew at 7%.

In addition to a powerful ecommerce presence, Blue Hat has long-term relationships with partnered distributors that place the company’s AR interactive entertainment products into well-known international retail chains and retail outlets. Blue Hat’s integrated online and offline sales channels include e-commerce giants such as Amazon and Alibaba, retail chain stores and the company’s physical experience store located in Xiamen, China. Blue Hat plans to open or franchise approximately 100 additional stores in China by 2021.

Blue Hat’s community-based platform offers users a highly engaged and interactive community with online communication forums and offline social activities. The company advocates a new model of “teaching through lively activities” and combines AR technology with education, integrating its products into situational teaching, roleplaying and man-machine interaction. This novel educational experience helps realize optimal transformation of information, creating a knowledge and enhancing cognition.

Management

Director and CEO Xiaodong (Sean) Chen has over 20 years of experience creating, developing and producing toys and games related products. Chen earned his EMBA from Renmin University of China and has been chairman of the board of directors and general manager of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

CFO and Director Caifan, who has over 20 years of financial accounting and taxation experience, earned a degree in finance from Hunan University of Finance and Economics. He has served as director, deputy general manager and financial controller of Fujian Blue Hat Interactive Entertainment Technology Ltd. since August 2015.

Jianyong Cai, chief technology officer and director, has over 35 years of experience in data communication principles, communication network foundation, software engineering, communication network theory and technology and computer network architecture. He holds degrees in data communication principles, communication network foundation and software engineering from University of Science and Technology of China. He has been director, deputy general manager and chief engineer of Fujian Blue Hat Interactive Entertainment Technology Ltd. since January 2010.

Blue Hat Interactive Entertainment Technology (BHAT), closed Friday’s trading session at $1.39, up 2.2059%, on 8,147,232 volume with 18,980 trades. The average volume for the last 3 months is 1,980,267 and the stock's 52-week low/high is $0.630800008/$2.40000009.

Recent News

• 5 Hot Penny Stocks To Watch As Chinese Tech Shares Lift On Friday
• Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Secures $7.59M in Registered Direct Offering
• InvestorNewsBreaks - Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Announces $7.59 Million Registered Direct Offering

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF).

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) announces that the Company has adopted an equity incentive plan (the "Incentive Plan") to supplement the Company's existing stock option plan (the "Option Plan"). Pursuant to the Incentive Plan, the Company may grant to eligible participants restricted share units ("RSUs") and deferred share units ("DSUs", together with RSUs, "Awards"). The aggregate number of Awards issuable under the Incentive Plan is subject to the same limits currently in place pursuant to the Option Plan. Pursuant to the Plan, the board of directors of the Company may select participants eligible to receive Awards, determine the type of Award to be granted, and establish the terms and conditions attached to the Awards. 

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: GHVNF), closed Friday’s trading session at $0.717, up 2.4286%, on 206840 volume with 69 trades. The average volume for the last 3 months is 97,621 and the stock's 52-week low/high is $0.109999999/$0.83069998.

Recent News

• GoldHaven Adopts Incentive Plan and Grants RSUs
• Legendary Mining Financier Forecasts Mining Industry Gains Resulting From Global Electrification
• An Overview of Key Lithium Extraction Projects Across the Globe

Grapefruit USA Inc. (OTCQB: GPFT)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit USA Inc. (OTCQB: GPFT).

Grapefruit USA Inc. (OTCQB: GPFT) was featured today in the 420 with CNW by CannabisNewsWire. Earlier this week, three leading advocates of cannabis reform stated that reform would be a priority in the new Democratic Senate in 2021, adding that they planned to release draft bills in the coming weeks to start a conversation about what federal policy changes would be made.

Grapefruit USA Inc. (OTCQB: GPFT) is a Delaware corporation that is a fully licensed premier cannabis manufacturer and distributor in the legal cannabis marketplace with its own patented and branded line of products.

The company manufactures its patented product line and distributes it, along with other cannabis products, to all properly licensed cannabis product businesses.

Grapefruit is the only cannabis company that has harnessed cutting edge science and technology to bring patented, truly disruptive products to the medicinal and recreational cannabis marketplace, fundamentally changing the way individuals use THC, CBDs and hemp-derived CBDs and capitalizing on the rise in demand for these unique products.

Headquartered in Los Angeles, California, the company has held licensing in the state for manufacturing and distributing cannabis since 2018. Grapefruit currently owns and operates a California-licensed cannabis extraction laboratory and a licensed wholesale distribution facility in the Coachillin’ Canna-Business Park near Palm Springs, California. Grapefruit is managed by a team of experts who possess the experience, skills and resources required to succeed in the competitive cannabis marketplace.

Hourglass™ Topical Delivery Cream

Grapefruit’s patented Hourglass™ topical delivery cream has solved the previously insurmountable difficulties of efficient skin absorption of THC and other cannabinoids.

Hourglass™ allows users to experience a sustained and holistic delivery of THC/cannabinoids providing “the entourage effect” following initial application to the skin. Additional applications may be made confidently and discreetly at the user’s discretion. There simply is no other product on the planet which successfully utilizes a patented time release THC and CBD delivery mechanism to deliver the holistic benefits of cannabis to those who need it.*

Hourglass™ is a unique, highly concentrated full spectrum time-release topical delivery cream that releases a holistic amount of THC, along with a wide range of cannabinoids (or just CBD), over a four- to eight-hour period.* The formula then comes off through the natural sloughing process of dead skin cells. Hourglass provides many holistic benefits, all of which promote health and wellness as it’s number one goal.

Hourglass™ provides users with an entourage effect of THC plus a wide range of cannabinoids, including CBD, Cannabinol (CBN), Cannabigerol (CBG), Delta-8, Tetrahydrocannabivarin (THCV), and Cannabielsoin (CBE) in a Patchless Patch™ system that is novel and proprietary to the company.

Hourglass™ Topical Delivery Cream has fundamentally changed the way individuals use THC and cannabinoids to obtain their holistic benefits.* As a result, smoking cannabis or hemp flowers and orally consuming edibles, which are metabolized in the gut and liver resulting in uneven reactions, are no longer the exclusive ways to receive both the medicinal and recreational benefits of THC/cannabinoids.* Now for the first time in history, there is an effective, easy to use third choice – Hourglass™ by Grapefruit.

*This product is not regulated by the FDA and is not intended to cure, mitigate, treat or prevent disease.

Grapefruit Cannabis Services

Grapefruit distributes cannabis flower and cannabis products, including its own proprietary products, as well as a wide range of services, to other properly licensed cannabis product businesses. These products and services include:

• Distribution – As a premier licensed distributor, Grapefruit handles the distribution of all-things cannabis throughout California, specializing in bulk AAA exotic indoor flowers sourced from farms located in the state. The wholesale distribution arm facilitates flowers, fresh and dry frozen, and oil transactions in bulk wholesale form. Its wholesale distribution arm distributes its patented Hourglass™ topical delivery cream.
• Manufacturing – The company owns and operates a fully licensed and compliant ethanol extraction lab that produces a high-quality distillate. This THC Honey Oil distillate is a universal product used in everything, including infused edibles, tinctures, creams and even vape cartridges. Its patented Hourglass™ cream is also manufactured exclusively at Grapefruit’s Coachillin lab facility by highly trained Grapefruit personnel.
• Hourglass™ Topical THC+CBD Delivery Cream – The company’s patented Hourglass™ Topical Delivery Cream has solved the inherent difficulties of efficient skin absorption of THC and cannabinoids such as CBD, CBN, CBG and CBC, as well as hemp-derived CBDs and cannabinoids. Hourglass™ is a truly novel and disruptive delivery technology which fundamentally changes the way individuals will use THC and CBD to obtain their holistic benefits.*
• Rainbow Dreams – Rainbow Dreams is the company’s lifestyle brand designed for the recreational cannabis marketplace. The brand captures the party-mode of the 1970s and offers vape carts with unique cannabis strains and natural flavors. The product fulfills an important marketplace niche – a top-shelf product that is competitively priced.

Market Outlook

The global cannabis market was valued at $10.6 billion in 2018. During the forecast period from 2019 to 2026, the market is expected to grow at a CAGR of 32.92%, reaching a projected value of $97.35 billion by the end of 2026 (https://nnw.fm/eTMSX).

Cannabis legalization has been gaining momentum around the world. Grapefruit is currently in a position to disrupt the industry – both the medicinal and recreational sectors – with proprietary products and manufacturing processes that harness the power of cutting-edge science and technology.

Management Team

Bradley J. Yourist is the Chief Executive Officer of Grapefruit. Mr. Yourist has been a follower of the medical cannabis market since the late 1990s, which allows him to understand the distribution model and the legal issues facing the market. He has also seen the benefit of cannabinoids in the medical industry. He understands the planning and operations of Grapefruit’s cannabis distribution arm and extraction lab and was instrumental in the planning for the facility.

Daniel J. Yourist is the Chief Operating Officer of Grapefruit. He is a licensed attorney in the state of California and a Real Estate Broker. Mr. Yourist is a licensing expert in the cannabis space and has gained extensive experience in all areas of managing a cannabis business in California. He ensures that every aspect of the company is run in accordance with state and local cannabis laws and regulations.

Grapefruit USA Inc. (OTCQB: GPFT), closed Friday’s trading session at $0.049, up 4.2553%, on 391,384 volume with 53 trades. The average volume for the last 3 months is 1,064,782 and the stock's 52-week low/high is $0.013624999/$0.103.

Recent News

• 420 with CNW - Democratic Senate Leaders Publicize Plan to Legalize Cannabis Federally in 2021
• Grapefruit USA Inc. (GPFT) Is 'One to Watch'
• CannabisNewsBreaks - Grapefruit USA Inc.'s (GPFT) Time Release THC+CBD Delivery Cream Available on Weedmaps Retail Website

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific (OTCQB: BRSF) is focused on developing innovative and proprietary medical devices and software. As the company works to modernize brain diagnostics through cutting-edge tech, it has also collaborated with Marketing Brainology, a neuromarketing firm that uses neuroscience to understand consumer behavior.

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

• NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

• NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

• NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
• NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

• Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
• An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

 

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Friday’s trading session at $1.50, even for the day, on 3,633 volume with 20 trades. The average volume for the last 3 months is 13,073 and the stock's 52-week low/high is $0.100000001/$3.00999999.

Recent News

• Brain Scientific Inc. (BRSF) Helps Identify Decision Triggers in Super Bowl Ads and COVID-19 Ads
• Brain Scientific Inc. (BRSF) Offers Possible Solution for Detecting and Studying Parkinson's
• BioMedNewsBreaks - Brain Scientific Inc. (BRSF) Marketing VP Authors Article on Increasing Need for Disposable Technologies

United Medical Equipment Business Solutions Network Inc.

The QualityStocks Daily Newsletter would like to spotlight United Medical Equipment Business Solutions Network Inc..

United Medical Equipment (“UME,” “UMEBSNI”) continues to move quickly to address the unique testing needs created by the ongoing global pandemic. UMEBSNI is a trusted supplier of FDA-approved COVID-19 rapid antigen test kits as part of its efforts to provide essential services during the epidemic. The company’s COVID-19 IgG/IgM Rapid Test Cassette detects coronavirus antibodies that appear in the bloodstream of individuals infected with the virus within 10 minutes.

Recent News

• NetworkNewsBreaks – United Medical Equipment Business Solutions Network Inc. Delivers Essential Solutions During Ongoing Pandemic
• United Medical Equipment Business Solutions Network Inc. to Thrive as High-Filtration Masks Gain Traction; Doctors Call for National Hi-Fi Mask Initiative
• United Medical Equipment Business Solutions Network Inc. Adds CareStart Antigen Test to List of COVID-19 Supplies

Hollywall Entertainment Inc. (OTC: HWAL)

The QualityStocks Daily Newsletter would like to spotlight Hollywall Entertainment Inc. (OTC: HWAL).

Telecommunication and broadcasting company Hollywall Entertainment (OTC: HWAL) has begun rolling out its new wholly owned subsidiary HW Vision to provide branded cellular equipment and services, streaming media content, live television and on-demand programming as part of Hollywall’s drive to become a major media and entertainment conglomerate. Also today, InvestorWire released a report featuring the company which details various investment considerations and how the company is “One to Watch.”

Hollywall Entertainment Inc. (OTC: HWAL) is a telecommunication, media, technology, broadcasting and entertainment company. Through various subsidiaries, Hollywall maximizes rights to its music, film, television, software and game libraries. Hollywall owns exclusive and nonexclusive rights to market, manufacture and distribute music master recordings performed by multiple platinum-selling acts.

Hollywall was founded in 2009. The company currently has two corporate offices – one in Washington D.C. and the other in New York City.

Hollywall Entertainment Inc. (Hollywall) Subsidiaries

Hollywall has a portfolio of operating subsidiaries spanning various industries, including infrastructure development, 5G and telecommunications, broadcasting, education, media and entertainment.

Hollywall is a minority majority-controlled consortium enterprise company led by founder and President/CEO Darnell Sutton, a highly recognized visionary and award-winning business and social leader.

HWAL continues to expand its business enterprise to numerous city and state municipalities and government agencies throughout the country, including: Washington DC, New York, Virginia, Massachusetts, Pennsylvania, Texas and California, as well as within the Blackbelt regions of Alabama, Louisiana, Mississippi, Georgia and North Carolina, leading the way in developing and implementing solutions to work toward closing the broadband digital divide that has been forced upon the most vulnerable in underserved urban and rural communities nationwide.

Hollywall Development Company (“HWDC”)

HWDC builds, restores and creates “smart” cities/communities and fiber networks throughout the U.S. HWDC services, initiatives and investments include broadband and 5G networks, IOT, smart city technologies, energy, tele-medicine, tele-education, transportation, clean water, waste management and the development of green environments.

HWDC employment growth opportunities continue to attract the industry’s best, brightest and most seasoned corporate executives to join its staff, as well as its ongoing efforts to develop highly effective and profitable strategic partnerships with investment banks, global capital funds, public financial and wealth management firms, construction and engineering companies, telecommunications companies, federal agencies, state and local governments, nonprofits, faith-based organizations and housing authorities.

HWDC’s Smart Cities division aims to provide various services and solutions, such as fiber-optic networking, data centers, smart kiosks, charging stations, security and camera systems, smart traffic monitoring, emergency alert systems, gunshot detection, backup power solutions, smart connected buildings, connected and autonomous vehicles, intelligent transportation systems, advertising and more.

HW Vision and Omnipoint Technology Inc.

Hollywall Entertainment advanced its technological footprint by acquiring top United States telecommunications firm Omnipoint Technology Inc. in 2020. Through the formation of a new wholly owned subsidiary, HW Vision, Hollywall intends to offer state-of-the-art services in the continuously growing digital marketplace, such as:

• 5G and Fiber Network installation services
• Affordable high-speed internet access
• Telehealth services
• Domain hosting
• Web conferencing
• Managed internet services
• Nationwide unlimited talk, text and data cellphone plans
• Video broadcasting

In conjunction with its Omnipoint Technology partner, HW Vision has created and developed unique branding for streaming media programming, live television and on-demand content. Offerings from the HW Vision brand are expected to be available for purchase early in 2021.

Hollywall Entertainment Digital Music Network and Hollywall TV

The Hollywall Entertainment Digital Music Network (“HW Network”) has been constructed to sell single song downloads, artist album downloads and ringtones, as well as licensing music for commercial use. Hollywall Music is an owner of legacy music and video collector sets that are distributed to retail, wholesale and download or streaming services. This music library has been protected for over 20 years, and it contains some of the rarest and most coveted unpublished records by legends in the music industry.

Market Outlook

Covering various industries that are continuously expanding, such as telecommunications, media, technology, construction, infrastructure, entertainment and broadcasting, Hollywall is uniquely positioned to secure a prominent role and leverage continued growth opportunities for its subsidiaries.

The 5G sector alone could generate significant interest and market opportunities for Hollywall via HWDC and its community-focused initiatives, including the development of smart cities. The global 5G market was estimated at $41.48 billion for 2020 and is expected to reach an impressive $414.5 billion by 2027, expanding at a CAGR of 43.9% (https://ibn.fm/mgXIu).

Management Team

Darnell Sutton is the Founder, CEO and Chairman of Hollywall Entertainment Inc. Mr. Sutton has over 40 years’ experience with many talents and vast experience as a veteran in the music recording industry, publishing, distribution, live entertainment, television, broadcasting, film and sports athlete, TV/film celebrity and artist management.

Darnell Sutton has represented and worked with some of the greatest athletes and entertainers of our time, including the “King of Pop” Michael Jackson, former heavyweight boxing champion Mike Tyson, current Welterweight Boxing Champion Floyd Mayweather, tennis superstar Serena Williams, Julius “Dr. J” Erving and incomparable multiple Grammy award-winning performers such as The Jacksons, Patti Labelle, Roberta Flack, MC Hammer, Dionne Warwick and Mariah Carey… just to name a few.

“Darnell Sutton, is one of the most exciting master communicators, creative developers and innovators of our time”…says, Tom Stein, Success Magazine.

“After many years of developing, producing and acquiring some of the world’s finest entertainment properties, we are honored to present Hollywall Entertainment companies to the marketplace. We are thrilled to join forces and work with some of the most brilliant and talented Hollywood and Wall Street executives, who have a combined shared experience of industry-recognized excellence,” Sutton said in a news release.

Roxanna Green is the Chief of Staff for Hollywall Entertainment Inc. She has over 30 years of diverse background experience ranging from corporate management to finance. Her experience includes providing corporate legal and financial guidance to both public and private companies, as well as spearheading audits, merger and acquisition negotiations, branding, marketing and public relations initiatives. She has spent the majority of her 30 years in the entertainment and media industry. She has worked with diverse institutions such as banks and securities firms, among others.

Hollywall Entertainment Inc. (OTC: HWAL), closed Friday’s trading session at $4.62, off by 5.7143%, on 15,893 volume with 99 trades. The average volume for the last 3 months is 4,608 and the stock's 52-week low/high is $0.611100018/$20.1100006.

Recent News

• Hollywall Entertainment Inc. (HWAL) Begins Roll-out of New HW Vision Media and Telecommunications Brand
• InvestorNewsBreaks - Why Hollywall Entertainment Inc. (HWAL) Is 'One to Watch'
• Hollywall Entertainment Inc. (HWAL) Is 'One to Watch'

Cybin Inc. (NEO: CYBN) (OTC: CLXPF)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (OTC: CLXPF).

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) was featured today in a publication from PsychedelicNewsWire, examining how psychedelics went mainstream last year, with more than 20 firms in the psychedelics industry getting listed publicly. The industry has also moved forward with regard to federal legalization, with some substances having received breakthrough therapy designations from the FDA. Also today, the company was featured in a publication from PsychedelicNewsWire, examining how Cybin’s subsidiary Serenity Life Sciences is engaged in the research and development of psilocybin-based medications. Widely referred to as magic mushrooms, Psilocybin has had its share of bad press. However, the company is positioned as perceptions of this substance are beginning to change. A recent article discussing this reads, “Under the Controlled Substances Act, psilocybin is included with heroin and LSD as a Schedule I drug. To view the full article, visit https://ibn.fm/f8YFM

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF), closed Friday’s trading session at $1.63, off by 4.6784%, on 493,608 volume with 989 trades. The average volume for the last 3 months is 408,654 and the stock's 52-week low/high is $0.0284/$2.23499989.

Recent News

• Experts Predict What 2021 Psychedelics Space Might Look Like
• PsychedelicNewsBreaks - Cybin Inc. (NEO: CYBN) Positioned Amid Growing Acceptance, Legalization of Psilocybin
• Cybin Announces Closing of Upsized Bought Deal Offering

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF)

The QualityStocks Daily Newsletter would like to spotlight Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF).

Holding company Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) recently announced a landmark definitive agreement between its investee company, PowerTap Hydrogen Fueling Corp. and the Humboldt Petroleum, Inc., Peninsula Petroleum, LLC, and Colvin Oil I LLC (dba GP Energy) companies that collectively are identified as “the Andretti Group.”

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity.

Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis.

Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq).

Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’.

PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration

In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp.

Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable.

Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development.

PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States.

Hydrogen Industry Outlook

The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry.

Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles.

“As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem).

A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050.

The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report.

With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap.

“As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added.

Management Team

Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings.

Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario.

Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies.

Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits.

Clean Power Capital Corp. (OTC: MOTNF), closed Friday’s trading session at $1.95, off by 3.4653%, on 220,783 volume with 334 trades. The average volume for the last 3 months is 228,972 and the stock's 52-week low/high is $0.0315/$2.78999996.

Recent News

• PowerTap, an Investee Company of Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6A) (OTC: MOTNF), Inks Hydrogen Fuel Deal with Andretti Group
• Factory Produces EV Batteries That Can Be Fully Charged in Five Minutes
• GreenCarNewsBreaks - Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) Appoints Michael Andretti to PowerTap Advisory Board

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

The QualityStocks Daily Newsletter would like to spotlight Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF).

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.

Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.

i/Blue Imaging™ System

The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal).

Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder.

Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.

The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment.

Bladder Cancer Prevalence

The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (https://ibn.fm/qLi3l).

Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates.

Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (https://ibn.fm/rI7G6).

Management Team

E. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation.

Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University.

Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), closed Friday’s trading session at $0.6434, off by 14.5891%, on 105,342 volume with 77 trades. The average volume for the last 3 months is 45,231 and the stock's 52-week low/high is $0.200000002/$1.16999995.

Recent News

• Imagin Medical Inc.'s (CSE: IME) (OTCQB: IMEXF) Proprietary System Could Help Reduce Bladder Cancer Recurrence
• BioMedNewsBreaks - Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Harnesses Blue Light, Innovative Technology for Cancer Imaging
• Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Technology Set to Revolutionize Bladder Cancer Visualization

Kaival Brands Innovations Group Inc. (KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (KAVL).

Kaival Brands Innovations Group Inc. (KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi™ Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi™ Stick.

Bidi™ Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi™ Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi™ Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (PMTA) to the U.S. Food and Drug Administration (FDA) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi™ Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi™ Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://nnw.fm/unAyG).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi™ Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi™ Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://nnw.fm/44sq4).

The positive results are primarily an effect of Bidi™ Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi™ Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://nnw.fm/W7s9T). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Kaival Brands Innovations Group Inc. (KAVL), closed Friday’s trading session at $1.80, up 25.00%, on 856166 volume with 1,001 trades. The average volume for the last 3 months is 623,552 and the stock's 52-week low/high is $0.008/$1.87.

Recent News

• InvestorNewsBreaks - Kaival Brands Innovations Group Inc. (KAVL) Enters Strategic Agreement with Potential to Triple Its Distribution Points
• InvestorNewsBreaks - Kaival Brands Innovations Group Inc. (KAVL) Announces New Bidi Pouch Product
• InvestorNewsBreaks - Kaival Brands Innovations Group Inc. (KAVL) Announces It Has Begun Process for NASDAQ Uplisting

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF)

The QualityStocks Daily Newsletter would like to spotlight Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF).

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF), headquartered in Pemberton, British Columbia, is a plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

The Company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

Market Position

The psychedelic and functional mushroom industries are among the fastest growing in North America. As the industry transitions from dry biomass to extracts, many companies are unprepared for this new opportunity. The global medicinal mushroom market is expected to grow by $13.88 billion annually by 2024.

When assessing investment strategy, market analysts suggest that psychedelics are more comparable to biotech than to cannabis. Unlike traditional biotech, however, psychedelics can claim years of human consumption. Because their efficacy and safety are already well understood, the hurdles for development are likely to be lower. As known molecules, psychedelics won’t spend as much time in discovery and pre-clinical development.

Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021.

Pure Extracts is well positioned to partner with organizations planning to develop both functional and psychedelic products. A dealer’s license with Health Canada will enable buying, selling and producing of psychedelics in an EU-GMP-compliant environment. The Company’s 10,000 square foot facility is designed for EU-GMP certification, which allows for international sales. The Company has signed NDAs to explore joint development endeavors for Q4 2020 product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.

Research on Psychedelics

Naturally occurring psychedelics, like psilocybin mushrooms, peyote and ayahuasca, have been used by humans for centuries. First seen as potentially medicinal in 1938 by a chemist at Sandoz Pharmaceuticals (now Novartis), the desired stimulant effect was unsuccessful and therefore the drug was shelved. Twenty years later, in 1958, Sandoz began selling lysergic acid diethylamide (LSD) to treat mental disorders. From 1950 to 1965, over a thousand scientific papers on these compounds were published. During the 1960s, however, psychedelics made their way out of the lab and onto the street. The war on drugs followed, and psychedelic research essentially ended.

Research continued slowly on the fringes. The Multidisciplinary Association for Psychedelic Studies was formed in 1986 with the goal of becoming a leading non-profit psychedelic pharmaceutical company. Still being researched, psychedelics’ primary and most common mechanism of action is agonism of serotonin receptors in the brain, which promotes serotonin production in order to regulate mood.

Growing societal awareness and acceptance of mental illness as a legitimate disease due, in part, to its increasingly prevalence have been a catalyst for a new search for innovative treatments. As such, interest in psychedelic medicines has been revived in recent years.

Extract Segment Leader with Cannabis

Canada’s cannabis industry is dominated by dried flower products. Extract products are estimated to represent only 13% of the market share. With no dominant brands in the cannabis sector, Pure Extracts is the development leader in this segment, which is estimated by Deloitte to be worth $2.7 billion annually. Pure Pulls, the company’s private label brand, is nationally recognized through compliant event sponsorship and ongoing product engagement.

Management Team

Pure Extracts is led by a team of dedicated professionals leveraging extensive industry knowledge.

Ben Nikolaevsky, the company’s CEO, has more than a decade of experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Nikolaevsky has served as CEO at Natura Naturals Inc. and Blue Goose Capital Corp., as well as market vice president at CIBC and chief credit officer & capital markets manager at IBM Global Financing Canada.

Doug Benville founded Pure Extracts and serves as the company’s COO. He is highly proficient in cannabis cultivation, system operations and oil extraction.

Alexander Logie, Pure Extracts’ vice president of business development, has over 30 years of experience in the financial services sector, having most recently served as interim CFO, COO and senior vice president of business development at Natura Naturals Inc., a licensed cannabis producer acquired at the start of 2019.

Andy Gauvin is vice president of sales for Pure Extracts. Gauvin is an accomplished senior sales leader with over 30 years of experience in the cannabis space. Gauvin also brings extensive knowledge of the complex federal and provincial regulatory environment to the Pure Extracts team.

Pure Extracts Technologies Corp. (PRXTF), closed Friday’s trading session at $0.5092, up 5.1849%, on 199,476 volume with 81 trades. The average volume for the last 3 months is 81,010 and the stock's 52-week low/high is $0.438603997/$1.00.

Recent News

• New Hawaii Senate Bill May See Psilocybin Mushroom Therapy Legalized
• Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Updates Investors Following Completion of Special Warrants Private Placement
• PsychedelicNewsBreaks - Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Completes New Company Registration for Class 1 NPN